GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Simcere Pharmaceutical Group Ltd (HKSE:02096) » Definitions » Net Cash per Share

Simcere Pharmaceutical Group (HKSE:02096) Net Cash per Share : HK$-0.67 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Simcere Pharmaceutical Group Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Simcere Pharmaceutical Group's Net Cash per Share for the quarter that ended in Dec. 2023 was HK$-0.67.

The historical rank and industry rank for Simcere Pharmaceutical Group's Net Cash per Share or its related term are showing as below:

HKSE:02096's Price-to-Net-Cash is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.13
* Ranked among companies with meaningful Price-to-Net-Cash only.

Simcere Pharmaceutical Group Net Cash per Share Historical Data

The historical data trend for Simcere Pharmaceutical Group's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Simcere Pharmaceutical Group Net Cash per Share Chart

Simcere Pharmaceutical Group Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Cash per Share
Get a 7-Day Free Trial -1.87 -1.08 -0.72 -0.43 -0.67

Simcere Pharmaceutical Group Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.72 -0.42 -0.43 -0.48 -0.67

Competitive Comparison of Simcere Pharmaceutical Group's Net Cash per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Simcere Pharmaceutical Group's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Simcere Pharmaceutical Group's Price-to-Net-Cash Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Simcere Pharmaceutical Group's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Simcere Pharmaceutical Group's Price-to-Net-Cash falls into.



Simcere Pharmaceutical Group Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Simcere Pharmaceutical Group's Net Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as

Net Cash per Share (A: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(2207.573-3971.436-0)/2616.72
=-0.67

Simcere Pharmaceutical Group's Net Cash per Share for the quarter that ended in Dec. 2023 is calculated as

Net Cash per Share (Q: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(2207.573-3971.436-0)/2616.72
=-0.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Simcere Pharmaceutical Group  (HKSE:02096) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Simcere Pharmaceutical Group Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Simcere Pharmaceutical Group's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Simcere Pharmaceutical Group (HKSE:02096) Business Description

Traded in Other Exchanges
Address
No. 699-18, Xuanwu Road, Xuanwu District, Jiangsu, Nanjing, CHN, 210042
Simcere Pharmaceutical Group Ltd is engaged in the R&D, production and commercialization of pharmaceuticals focused on generic pharmaceuticals. It has a diversified product portfolio focused on therapeutic areas, including, oncology (including cell therapy), nervous system diseases, autoimmune diseases and antiinfection. The company's products include Endostar, Enweida, Iremod, Sanbexin and Others.
Executives
Wang Xi 2305 Beneficiary of a trust
Ren Jinsheng 2202 Interest of your spouse
Right Wealth Holdings Limited 2501 Other
Wang Xi 2501 Other
Simcere Investments Group Limited 2501 Other
Excel Investments Group Limited 2501 Other
Simcere Pharmaceutical Holding Limited 2501 Other
Simcere Holding Limited 2501 Other
Artking Global Limited 2501 Other
Ren Zhen 2501 Other
Ren Yong 2501 Other
Ren Weidong 2501 Other
Peng Suqin 2501 Other
P&h Holdings Group Ltd. 2501 Other
Li Shimeng 2501 Other

Simcere Pharmaceutical Group (HKSE:02096) Headlines

No Headlines